ARIAD Pharmaceuticals (ARIA): Price Target and June Short Interest Disclosure

ARIAD Pharmaceuticals (ARIA) : The consensus price target for ARIAD Pharmaceuticals (ARIA) is $10.4 for the short term with a standard deviation of $2.07. The most optimist securities analyst among the 5 who monitor the stock believes that the stock can reach $13, however, the pessimist price target for the company is $8.

ARIAD Pharmaceuticals (ARIA), A drop of 1,199,832 shares or 3.5% was seen in the short interest of ARIAD Pharmaceuticals, Inc.. Even as the interest dropped from 34,123,404 shares on June 15,2016 to 32,923,572 shares on June 30,2016, the days to cover came in at 7. The updated interest stood at 17.9% of the stocks floats. The stock has seen an average daily volume of 4,960,522 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.

Also, In the latest statement by the brokerage house, Cowen & Company upgrades its outlook on ARIAD Pharmaceuticals (NASDAQ:ARIA). The current rating of the shares is Outperform, according to the research report released by the firm. Previously, the company had a rating of Market Perform. The rating by the firm was issued on May 5, 2016.


ARIAD Pharmaceuticals (NASDAQ:ARIA): On Thursdays trading session , Opening price of the stock was $7.21 with an intraday high of $7.24. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $7. However, the stock managed to close at $7.03, a loss of 1.54% for the day. On the previous day, the stock had closed at $7.14. The total traded volume of the day was 2,553,886 shares.

ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.